What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation?

Journal of Cardiology

Volumn 57, Issue 1, 2011, Pages 53-60

  Park, Keun Ho ^a   Jeong, Myung Ho ^a   Lee, Min Goo ^a   Ko, Jum Suk ^a   Sim, Doo Sun ^a   Yoon, Nam Sik ^a   Yoon, Hyun Ju ^a   Hong, Young Joon ^a   Kim, Kye Hun ^a   Park, Hyung Wook ^a   Kim, Ju Han ^a   Ahn, Youngkeun ^a   Cho, Jeong Gwan ^a   Park, Jong Chun ^a   Kang, Jung Chaee ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

Cilostazol; Myocardial infarction; Platelets; Stents

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ACUTE HEART INFARCTION; ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; DRUG ELUTING STENT; FEMALE; HEART DEATH; HUMAN; IMPLANTATION; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; REVASCULARIZATION; STENT THROMBOSIS; TREATMENT DURATION;

ASPIRIN; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RECURRENCE; RETROSPECTIVE STUDIES; TETRAZOLES; TICLOPIDINE; TIME FACTORS;

EID: 78650560445     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2010.10.002     Document Type: Article

References (31)

1. Kirtane A.J., Gupta A., Iyengar S., Moses J.W., Leon M.B., Applegate R., Brodie B., Hannan E., Harjai K., Jensen L.O., Park S.J., Perry R., Racz M., Saia F., Tu J.V., et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009, 119:3198-3206.
2. Mauri L., Silbaugh T.S., Garg P., Wolf R.E., Zelevinsky K., Lovett A., Varma M.R., Zhou Z., Normand S.L. Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 2008, 359:1330-1342.
3. Brar S.S., Leon M.B., Stone G.W., Mehran R., Moses J.W., Brar S.K., Dangas G. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol 2009, 53:1677-1689.
4. Stone G.W., Lansky A.J., Pocock S.J., Gersh B.J., Dangas G., Wong S.C., Witzenbichler B., Guagliumi G., Peruga J.Z., Brodie B.R., Dudek D., Mockel M., Ochala A., Kellock A., Parise H., et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009, 360:1946-1959.
5. Valgimigli M., Campo G., Percoco G., Bolognese L., Vassanelli C., Colangelo S., de Cesare N., Rodriguez A.E., Ferrario M., Moreno R., Piva T., Sheiban I., Pasquetto G., Prati F., Nazzaro M.S., et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008, 299:1788-1799.
6. Lee S.R., Jeong M.H., Ahn Y.K., Chae S.C., Hur S.H., Kim Y.J., Seong I.W., Chae J.K., Hong T.J., Rhew J.Y., Cho M.C., Bae J.H., Rha S.W., Kim C.J., Jang Y.S., et al. Clinical safety of drug-eluting stents in the Korea acute myocardial infarction registry. Circ J 2008, 72:392-398.
7. Daemen J., Wenaweser P., Tsuchida K., Abrecht L., Vaina S., Morger C., Kukreja N., Juni P., Sianos G., Hellige G., van Domburg R.T., Hess O.M., Boersma E., Meier B., Windecker S., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007, 369:667-678.
8. Park D.W., Park S.W., Park K.H., Lee B.K., Kim Y.H., Lee C.W., Hong M.K., Kim J.J., Park S.J. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006, 98:352-356.
9. Chen K.Y., Rha S.W., Li Y.J., Poddar K.L., Jin Z., Minami Y., Wang L., Kim E.J., Park C.G., Seo H.S., Oh D.J., Jeong M.H., Ahn Y.K., Hong T.J., Kim Y.J., et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009, 119:3207-3214.
10. Han Y., Li Y., Wang S., Jing Q., Wang Z., Wang D., Shu Q., Tang X. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009, 157:733-739.
11. Park K.H., Jeong M.H., Lee M.G., Ko J.S., Lee S.E., Kang W.Y., Kim S.H., Sim D.S., Yoon N.S., Youn H.J., Hong Y.J., Park H.W., Kim J.H., Ahn Y., Cho J.G., et al. Efficacy of triple anti-platelet therapy including cilostazol in acute myocardial infarction patients undergoing drug-eluting stent implantation. Korean Circ J 2009, 39:190-197.
12. King S.B., Smith S.C., Hirshfeld J.W., Jacobs A.K., Morrison D.A., Williams D.O., Feldman T.E., Kern M.J., O'Neill W.W., Schaff H.V., Whitlow P.L., Adams C.D., Anderson J.L., Buller C.E., Creager M.A., et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on the 2005 Writing Committee. Circulation 2008, 117:261-295.
13. Lee S.W., Park S.W., Kim Y.H., Yun S.C., Park D.W., Lee C.W., Hong M.K., Kim H.S., Ko J.K., Park J.H., Lee J.H., Choi S.W., Seong I.W., Cho Y.H., Lee N.H., et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008, 51:1181-1187.
14. Rao A.K., Pratt C., Berke A., Jaffe A., Ockene I., Schreiber T.L., Bell W.R., Knatterud G., Robertson T.L., Terrin M.L. Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988, 11:1-11.
15. D'Agostino R.B. Propensity scores in cardiovascular research. Circulation 2007, 115:2340-2343.
16. Stone G.W., Moses J.W., Ellis S.G., Schofer J., Dawkins K.D., Morice M.C., Colombo A., Schampaert E., Grube E., Kirtane A.J., Cutlip D.E., Fahy M., Pocock S.J., Mehran R., Leon M.B. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007, 356:998-1008.
17. Kaltoft A., Jensen L.O., Maeng M., Tilsted H.H., Thayssen P., Bottcher M., Lassen J.F., Krusell L.R., Rasmussen K., Hansen K.N., Pedersen L., Johnsen S.P., Sorensen H.T., Thuesen L. 2-Year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry). J Am Coll Cardiol 2009, 53:658-664.
18. Kastrati A., Mehilli J., Pache J., Kaiser C., Valgimigli M., Kelbaek H., Menichelli M., Sabate M., Suttorp M.J., Baumgart D., Seyfarth M., Pfisterer M.E., Schomig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007, 356:1030-1039.
19. Di Lorenzo E., Sauro R., Varricchio A., Carbone G., Cortese G., Capasso M., Lanzillo T., Manganelli F., Mariello C., Siano F., Pagliuca M.R., Stanco G., Rosato G., De Luca G. Long-term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial. Circulation 2009, 120:964-972.
20. Nakazawa G., Finn A.V., Joner M., Ladich E., Kutys R., Mont E.K., Gold H.K., Burke A.P., Kolodgie F.D., Virmani R. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 2008, 118:1138-1145.
21. Kimura Y., Tani T., Kanbe T., Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985, 35:1144-1149.
22. Tanaka T., Ishikawa T., Hagiwara M., Onoda K., Itoh H., Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 1988, 36:313-320.
23. Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 2005, 6:3-11.
24. Lee S.W., Park S.W., Hong M.K., Kim Y.H., Lee B.K., Song J.M., Han K.H., Lee C.W., Kang D.H., Song J.K., Kim J.J., Park S.J. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005, 46:1833-1837.
25. Jeong Y.H., Lee S.W., Choi B.R., Kim I.S., Seo M.K., Kwak C.H., Hwang J.Y., Park S.W. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 2009, 53:1101-1109.
26. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., Michev I., Corvaja N., Briguori C., Gerckens U., Grube E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293:2126-2130.
27. Tsuchikane E., Fukuhara A., Kobayashi T., Kirino M., Yamasaki K., Izumi M., Otsuji S., Tateyama H., Sakurai M., Awata N. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999, 100:21-26.
28. Douglas J.S., Holmes D.R., Kereiakes D.J., Grines C.L., Block E., Ghazzal Z.M., Morris D.C., Liberman H., Parker K., Jurkovitz C., Murrah N., Foster J., Hyde P., Mancini G.B., Weintraub W.S. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005, 112:2826-2832.
29. Takahashi S., Oida K., Fujiwara R., Maeda H., Hayashi S., Takai H., Tamai T., Nakai T., Miyabo S. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol 1992, 20:900-906.
30. Pan X., Arauz E., Krzanowski J.J., Fitzpatrick D.F., Polson J.B. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol 1994, 48:827-835.
31. Grines C.L., Goldstein J.A., Safian R.D. Should we routinely use drug-eluting stents for acute myocardial infarction? Let's wait and see. JACC Cardiovasc Interv 2008, 1:136-138.